| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medical Specialties (S.P., C.N.), The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; and Department of Chemistry (B.T.W., J.-K.L., G.H.P.), Johns Hopkins University, Baltimore, Maryland 21218
Analogs of 1,25-dihydroxyvitamin D3 (1,25D3) can be used to elucidate details of vitamin D receptor (VDR) activation. The A ring-modified analog, (TN-2) has 15-fold less affinity for VDR, but its transcriptional activity is diminished 1000-fold. Likewise, the ability of TN-2 to induce a protease- resistant conformation in VDR is 1/1000 that of 1,25D3. The stability of the VDR-TN-2 complexes is also significantly lower than VDR-1,25D3 complexes. Mapping the VDR-binding site of TN-2 showed that it had a significantly greater requirement for transcription activation function 2 (AF-2) residues than 1,25D3 did. These results suggest that the increased requirement for AF-2 residues that was induced by the A ring modifications is associated with diminished receptor activation. To determine whether restoring the potency of TN-2 by additional structural modifications would change the requirements for AF-2 residues, we synthesized hybrid analogs with 1ß-hydroxymethyl-3-epi groups and with dimethyl groups at positions 26 and 27 of the side chain, without or with a double bond between CD ring positions 16 and 17. We found that the side chain modification enhanced transcriptional activity 150-fold, increased the ability of the receptor to form a protease-resistant conformation 100-fold, and stabilized the VDR-analog complexes. The addition of the 16-ene group further reduced the analog’s dissociation rate and increased its potency in the protease assays. These functional changes in the hybrid analogs were associated with a significant reduction in interaction with AF-2 residues. We conclude that there is an inverse relationship between analogs’ potencies and their interaction with AF-2 residues of VDR.
This article has been cited by other articles:
 |
|
 |
|
  L. A. Zella, M. B. Meyer, R. D. Nerenz, and J. W. Pike The Enhanced Hypercalcemic Response to 20-Epi-1,25-Dihydroxyvitamin D3 Results from a Selective and Prolonged Induction of Intestinal Calcium-Regulating Genes Endocrinology, August 1, 2009; 150(8): 3448 - 3456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ismail, C. V. Nguyen, A. Ahene, J. C. Fleet, M. R. Uskokovic, and S. Peleg Effect of Cellular Environment on the Selective Activation of the Vitamin D Receptor by 1{alpha},25-Dihydroxyvitamin D3 and Its Analog 1{alpha}-Fluoro-16-Ene-20-Epi-23-Ene-26,27-Bishomo-25-Hydroxyvitamin D3 (Ro-26-9228) Mol. Endocrinol., April 1, 2004; 18(4): 874 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Malloy, R. Xu, L. Peng, P. A. Clark, and D. Feldman A Novel Mutation in Helix 12 of the Vitamin D Receptor Impairs Coactivator Interaction and Causes Hereditary 1,25-Dihydroxyvitamin D-Resistant Rickets without Alopecia Mol. Endocrinol., November 1, 2002; 16(11): 2538 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-Y. Liu, C. Nguyen, and S. Peleg Regulation of Ligand-Induced Heterodimerization and Coactivator Interaction by the Activation Function-2 Domain of the Vitamin D Receptor Mol. Endocrinol., November 1, 2000; 14(11): 1776 - 1787. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. W. Kensler, P. M. Dolan, S. J. Gange, J.-K. Lee, Q. Wang, and G. H. Posner Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis Carcinogenesis, July 1, 2000; 21(7): 1341 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Feldman, X.-Y. Zhao, and A. V. Krishnan Editorial/Mini-Review: Vitamin D and Prostate Cancer Endocrinology, January 1, 2000; 141(1): 5 - 9. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ozono, M. Saito, D. Miura, T. Michigami, S. Nakajima, and S. Ishizuka Analysis of the Molecular Mechanism for the Antagonistic Action of a Novel 1alpha ,25-Dihydroxyvitamin D3 Analogue toward Vitamin D Receptor Function J. Biol. Chem., November 5, 1999; 274(45): 32376 - 32381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hofer, G.-m. Ho, M. Peterlik, M. R. Uskokovic, J. K. Lee, M. C. White, G. H. Posner, and H. S. Cross Biological Effects of 1alpha -Hydroxy- and 1beta -(Hydroxymethyl)-Vitamin D Compounds Relevant for Potential Colorectal Cancer Therapy J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 450 - 455. [Abstract] [Full Text]
|
|
|
|
|
|
A. Racz and J. Barsony Hormone-dependent Translocation of Vitamin D Receptors Is Linked to Transactivation J. Biol. Chem., July 2, 1999; 274(27): 19352 - 19360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Quack and C. Carlberg Selective Recognition of Vitamin D Receptor Conformations Mediates Promoter Selectivity of Vitamin D Analogs Mol. Pharmacol., June 1, 1999; 55(6): 1077 - 1087. [Abstract] [Full Text]
|
|
|
|
|
|
S. A. Gardezi, C. Nguyen, P. J. Malloy, G. H. Posner, D. Feldman, and S. Peleg A Rationale for Treatment of Hereditary Vitamin D-resistant Rickets with Analogs of 1alpha ,25-Dihydroxyvitamin D3 J. Biol. Chem., July 27, 2001; 276(31): 29148 - 29156. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
